Khurshid Guru, MD, director of the Center for Robotic Surgery at Roswell Park Cancer Institute, Buffalo, NY, has been named the Dr. Robert P. Huben Professor of Urologic Oncology.
Khurshid Guru, MD, director of the Center for Robotic Surgery at Roswell Park Cancer Institute, Buffalo, NY, has been named the Dr. Robert P. Huben Professor of Urologic Oncology.
The Huben Professorship in Urologic Oncology was established in 2006 to support urologic education and research. It was first held by Robert Huben, MD, prior to his death from cancer in October 2011.
Dr. Guru’s major interest is robotic surgical education and its incorporation for future generations of surgeons. The annual funds provided by the Huben Professorship endowment will be used to help expand robotic/surgical training and education opportunities.
"Dr. Huben was beloved by so many patients for his outstanding care, and made such an impact for the field that it is a great honor to be able to continue that momentum and all he stood for," said Dr. Guru, who is also an associate professor of oncology in the department of urology at Roswell Park and clinical assistant professor of urology in the University at Buffalo School of Medicine and Biomedical Sciences. "I will try my best to carry the Bob Huben legacy and Roswell Park mission forward."
Dr. Guru and the Roswell Park team pioneered RPCI’s program for robotic cystectomy; he performed the first robot-assisted cystectomy in Western New York in November 2005. Dr. Guru has performed live demonstrations of robot-assisted prostatectomy at several international seminars.
Go back to this issue of Urology Times eNews.
Related Content
Dr. Canfield named urology chief at UTHealth
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.